SCHEDULE: LakeShore Biopharma Take-Private Bid at $0.86/Share

A consortium of investors, including major shareholders, has proposed to acquire all outstanding shares of LakeShore Biopharma Co., Ltd. not already owned by them for $0.86 per share, aiming to take the company private.

Summary

• A consortium of investors has proposed to acquire all outstanding ordinary shares of LakeShore Biopharma Co., Ltd. not currently owned by them.
• The proposed acquisition price is US$0.86 per ordinary share in an all-cash transaction.
• This offer represents a 10.3% premium to the last closing price on August 15, 2025, and an 11.4% premium to the average closing price over the prior 15 trading days.
• The consortium, initially formed by Oceanpine Investment Fund II LP, Oceanpine Capital Inc., and Crystal Peak Investment Inc., has expanded to include Adjuvant Global Health Technology Fund, L.P., Adjuvant Global Health Technology Fund DE, L.P., MSA Growth Fund II, L.P., Superstring Capital Master Fund LP, and Epiphron Capital (Hong Kong) Limited.
• The consortium collectively beneficially owns approximately 52.1% of LakeShore Biopharma's outstanding ordinary shares.
• The transaction aims to delist LakeShore Biopharma from NASDAQ (or cease quotation on OTC Pink Open Market) and deregister it under the U.S. Securities Exchange Act of 1934.
• The funding for the proposed transaction will come from rollover equity and available cash on hand, with no debt financing condition.

Sentiment

Score: 7

Explanation: The filing details a take-private proposal at a premium to recent trading prices, which is generally positive for existing public shareholders. The consortium's significant ownership and commitment to an all-cash, non-debt-contingent deal increase the likelihood of success. However, the delisting removes future public market participation.

Positives

• The proposed acquisition price of US$0.86 per share offers a 10.3% premium over the last closing price on August 15, 2025.
• The offer provides a 11.4% premium over the 15-day average closing price, offering compelling value to shareholders.
• The transaction is not subject to debt financing, reducing uncertainty and potential delays.
• The consortium, holding over 50% of outstanding shares, has agreed to vote in favor of the transaction, increasing the likelihood of approval.

Negatives

• The proposed transaction will result in LakeShore Biopharma Co., Ltd. being delisted from NASDAQ (or ceasing quotation on OTC Pink Open Market) and deregistered, removing its public trading status.
• Unaffiliated shareholders will no longer have an opportunity to participate in the company's future growth as a publicly traded entity.

Risks

• The proposed transaction is subject to the formation of a special committee of independent directors and their recommendation.
• Negotiation and finalization of definitive agreements are required.
• The transaction is subject to customary due diligence.
• Potential for disagreements among consortium members on material terms of the transaction or with the Special Committee.
• Risk of an "Alternative Transaction" being proposed by a third party, though consortium members are bound by exclusivity.

Future Outlook

The consortium intends to complete the proposed take-private transaction, which would result in LakeShore Biopharma Co., Ltd. being delisted from NASDAQ (or ceasing quotation on OTC Pink Open Market) and deregistered under the U.S. Securities Exchange Act of 1934. The company's business is expected to continue operating generally consistent with its current operations post-transaction.

Management Comments

• "We believe that our Proposal represents an attractive opportunity for the Company's shareholders to receive compelling value as compared with the current and recent trading prices of the Ordinary Shares."
• "We intend to fund the Proposed Transaction with rollover equity and available cash on hand. Accordingly, our Proposal would not be subject to any uncertainty or delay with respect to any debt financing, and the Proposed Transaction will not be subject to a financing condition."
• "We are confident that we can complete customary due diligence in a timely manner, in parallel with discussions on the definitive agreements."
• "We, as the initial members of the Consortium, have entered into a consortium agreement dated as of the date hereof, pursuant to which we have agreed to vote all of the Ordinary Shares of the Company beneficially owned by us in favor of the Proposed Transaction and do not intend to sell our Ordinary Shares of the Company to any third party or support any competing bid to our Revised Proposal while remaining as members of the Consortium."
• "Given our knowledge of the Company, we remain committed to completing the Proposed Transaction in an expedited manner by promptly engaging in discussions with the Special Committee and its advisors to negotiate and finalize the definitive documentation relating to the Proposed Transaction, so as to expedite the process of delivering value to the Company's shareholders."

Industry Context

The proposed take-private transaction for LakeShore Biopharma Co., Ltd. aligns with a broader trend of private equity and investment firms seeking to acquire public companies, particularly in specialized sectors like biopharma, to unlock value away from public market scrutiny. Such transactions often occur when public market valuations are perceived as undervalued or when significant restructuring or long-term investment is required that is better managed in a private setting. The involvement of multiple investment funds (Oceanpine, Adjuvant, MSA, Superstring, Epiphron) highlights a collaborative approach to financing and executing complex acquisitions in the biopharma space.

Comparison to Industry Standards

• The proposed premium of 10.3% to the last closing price and 11.4% to the 15-day average closing price is within the typical range for take-private transactions, which often see premiums between 10-30%. For example, recent take-private deals in the biopharma sector have shown varying premiums depending on market conditions, company specifics, and competitive bids.
• The consortium's significant existing ownership (over 50%) is a strong indicator of commitment and increases the likelihood of the deal's success, often seen in successful management-led or insider-led buyouts.
• The all-cash nature of the offer, without a debt financing condition, is a positive signal, often preferred by target company boards and shareholders as it reduces execution risk compared to deals reliant on external debt.

Corporate Governance

Related Party Transactions

• The entire proposed acquisition is a related party transaction, as the consortium members are existing significant shareholders of LakeShore Biopharma Co., Ltd.
• The consortium members have entered into a Consortium Agreement to jointly pursue the take-private transaction.
• The transaction involves existing shareholders (including Huaqin Xue, Crystal Peak, Oceanpine, Adjuvant, MSA Growth, Superstring Capital, and Epiphron Capital) rolling over their equity into a new holding company (Holdco) formed for the acquisition.

Stakeholder Impact

• Shareholders: Unaffiliated shareholders are offered a premium for their shares, providing an exit opportunity. However, they will lose the ability to participate in the company's future growth as a publicly traded entity.
• Company (LakeShore Biopharma): Will transition from a public to a private company, reducing regulatory compliance burdens and potentially allowing for more long-term strategic decisions without public market pressure.
• Consortium Members: Will gain full control of LakeShore Biopharma, allowing them to implement their strategic vision and potentially realize greater value from the company's operations.
• Employees: The filing states the consortium intends for the company's business to continue operating generally consistent with its current operations, suggesting minimal immediate impact on employees.

Next Steps

• LakeShore Biopharma's Board of Directors is expected to form a special committee of independent and disinterested directors to evaluate the Revised Proposal.
• The Special Committee will retain its own independent legal and financial advisors.
• Negotiation and finalization of definitive agreements (e.g., Merger Agreement, Shareholders Agreement) between the consortium and the Company.
• Consummation of the proposed acquisition transaction.
• Delisting of LakeShore Biopharma from NASDAQ (or cessation of quotation on OTC Pink Open Market) and deregistration under the U.S. Securities Exchange Act of 1934.

Key Dates

Recommendation

The proposed take-private transaction offers a premium to recent trading prices, which is favorable for existing shareholders. However, the deal is still preliminary and subject to the formation of a special committee, due diligence, and negotiation of definitive agreements. While the consortium's significant ownership and all-cash, non-debt-contingent funding increase the likelihood of success, there remains execution risk. A "hold" recommendation is appropriate for investors to await further developments and the finalization of the definitive agreements, as the current offer provides a clear exit strategy at a premium, but there's no immediate catalyst for further significant upside beyond the offer price unless a competing bid emerges.

Keywords

LakeShore Biopharma, take-private, privatization, Schedule 13D, Oceanpine Capital, Crystal Peak, Adjuvant Capital, MSA Growth Fund, Superstring Capital, Epiphron Capital, biopharma investment, equity rollover, share acquisition, delisting, SEC filing